escitalopram has been researched along with Depression, Involutional in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (1.52) | 24.3611 |
| 2020's | 65 (98.48) | 2.80 |
| Authors | Studies |
|---|---|
| Bang-Andersen, B; Frederiksen, K; Hogg, S; Jensen, KG; Jørgensen, M; Mørk, A; Nielsen, SM; Ruhland, T; Smith, G; Stensbøl, TB; Zhong, H | 1 |
| Filippini, N; Godlewska, BR; Harmer, CJ; Martens, MAG | 1 |
| Abdallah, MS; Abo Mansour, HE; Elsawah, HK; Elsokary, MA; Mansour, NO; Mosalam, EM; Omara-Reda, H; Ramadan, AN; Zaki, SA | 1 |
| Cao, L; Chen, Y; Fang, Y; Hong, W; Huang, H; Huang, Q; Kong, S; Lyu, D; Peng, D; Qian, N; Wang, F; Wei, Z; Wu, C; Wu, Z; Yang, W; Zhang, M; Zhao, J | 1 |
| Cai, Y; Cao, L; Fang, Y; Hong, W; Peng, D; Su, Y; Wang, F; Wu, Z; Zhang, H | 1 |
| Arnott, SR; Ballester, PL; Frey, BN; Hassel, S; Kennedy, SH; Lam, RW; Milev, R; Minuzzi, L; Müller, DJ; Nogovitsyn, N; Sassi, RB; Strother, SC; Suh, JS; Taylor, VH | 1 |
| Aitchison, KJ; Farmer, AE; Hauser, J; Keers, R; Köhler-Forsberg, O; Maier, W; McGuffin, P; Mors, O; Rietschel, M; Uher, R | 1 |
| Chen, X; Cui, J; Feng, Y; Liu, R; Wang, G; Wang, Y; Zhang, Z; Zhou, J; Zhou, Y | 1 |
| Bhat, V; Demchenko, I; Frey, BN; Ho, K; Kennedy, SH; Khoo, Y; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Ravindran, AV; Rotzinger, S | 1 |
| He, Y; Liu, F; Sun, Z; Wang, G; Wang, H; Wong, AHC; Yang, J; Zhou, J; Zhu, X | 1 |
| Allen, TA; Blier, P; Dhami, P; Farzan, F; Foster, JA; Frey, BN; Kennedy, SH; Kloiber, S; Lam, RW; MacQueen, G; Milev, R; Müller, DJ; Parikh, SV; Quilty, LC; Rotzinger, S; Schwartzmann, B; Soares, CN; Strother, SC; Turecki, G; Uher, R | 1 |
| Asada, R; Hori, H; Kawasaki, H; Ogushi, Y | 1 |
| Chen, J; Lan, X; Lao, G; Li, G; Li, W; Ning, Y; Wang, C; Wu, K; Zhang, M; Zhang, Z; Zhou, Y | 1 |
| Bleich, S; Bridler, R; de Bardeci, M; Greil, W; Grohmann, R; Hasler, G; Kasper, S; Köberle, U; Rüther, E; Seifert, J; Stassen, H; Toto, S; Willms, J | 1 |
| Bhatia, V; Chopra, B; Dhingra, AK; Guarve, K | 1 |
| Chen, X; Feng, L; Feng, Y; Sun, Z; Xiao, L; Yang, J; Zhou, J | 1 |
| Bhat, V; Demchenko, I; Espinola, CW; Frey, BN; Ho, K; Kennedy, SH; Khoo, Y; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Parmar, R; Ravindran, AV; Rotzinger, S | 2 |
| Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A | 1 |
| Carhart-Harris, R; Daws, RE; Erritzoe, D; Giribaldi, B; Nutt, D; Roseman, L; Sexton, JD; Timmermann, C; Wall, MB | 1 |
| Bhat, V; Diep, C; Frey, BN; Gandhi, W; Kennedy, SH; Khoo, Y; Ladha, KS; Lam, RW; Lou, W; Milev, RV; Ravindran, AV; Rosenek, N; Rotzinger, S; Salomons, T; van Reekum, CM | 1 |
| Cho, RY; Fang, F; Godlewska, B; Savitz, SI; Selvaraj, S; Zhang, Y | 1 |
| Fuchikami, M; Itai, E; Kamishikiryo, T; Masuda, Y; Mawatari, K; Numata, S; Ohmori, T; Okada, G; Okamoto, Y; Takahashi, A; Takamura, M; Yokoyama, S; Yoshino, A | 1 |
| Alexandre, M; Economos, G; Glehen, O; Haesebaert, J; Perceau-Chambard, E; Subtil, F; Villeneuve, L | 1 |
| Behle, N; Brendel, M; Chrobok, A; Karch, S; Keeser, D; Koch, W; Koller, G; Krause, D; Manz, KM; Pogarell, O; Rominger, A | 1 |
| Farzan, F; Foster, JA; Frey, BN; Husain, MI; Kennedy, SH; Kim, HK; Kloiber, S; Lam, RW; Milev, R; Müller, DJ; Mulsant, BH; Parikh, SV; Soares, CN; Tripathy, SJ; Turecki, G; Zai, G | 1 |
| Alexopoulos, GS; Avari, J; Dunlop, K; Gunning, FM; Hoptman, MJ; Ilieva, I; Oberlin, LE; Victoria, LW | 1 |
| Arnott, SR; Davis, AD; Frey, BN; Greiner, R; Hall, GB; Harris, JK; Hassel, S; Kennedy, SH; Lam, RW; MacQueen, GM; Milev, R; Müller, DJ; Rotzinger, S; Strother, SC; Zamyadi, M | 1 |
| Andrade, NM; Arent, CO; Barichello, T; Bencke, CV; Biehl, E; Bonfante, S; Borba, LA; Botelho, MEM; Carlessi, AS; Collodel, A; de Moura, AB; Generoso, CM; Generoso, JS; Joaquim, L; Lodetti, BF; Maciel, LR; Manosso, LM; Martinello, NS; Padilha, APZ; Petronilho, F; Quevedo, J; Réus, GZ | 1 |
| Dörfler, S; Gründer, G; Hart, XM; Havemann-Reinecke, U; Heesen, S; Hiemke, C; Schmitz, CN; Wedekind, D | 1 |
| Brunoni, AR; Diaz, AP; Goerigk, S; Luethi, MS; Soares, JC; Suen, P; Zanao, TA | 1 |
| Cai, JF; Chen, GB; He, JK; Hou, XB; Jiao, Y; Jin, GX; Liu, Y; Qin, ZS; Rong, PJ; Shi, L; Wang, Y; Wong, YK; Xiao, HB; Xiao, X; Xu, FQ; Yang, XJ; Zhang, JN; Zhang, LL; Zhang, SY; Zhang, ZJ; Zhao, YY; Zheng, Y | 1 |
| Ahmed, R; Albert, K; Andrews, P; Begnoche, P; Boyd, BD; Elson, D; Kang, H; Landman, BA; Szymkowicz, SM; Taylor, WD; Vega, J | 1 |
| Brown, R; Carroll, C; Duncan, G; Freemantle, N; Grover, L; Hunter, R; Lewis, G; Molloy, S; Schrag, A; Serfaty, MA; Whipps, J | 1 |
| Amada, N; Futamura, T; Hirose, T; Kakumoto, Y; Kikuchi, T; Maeda, K; Suzuki, M | 1 |
| Cha, J; Choi, KS; Craighead, WE; Dunlop, BW; Mayberg, HS; Nemeroff, CB; Rajendra, JK | 1 |
| Armand, S; Borgsted, C; Cardinal, RN; Johansen, A; Knudsen, GM; Langley, C; Luo, Q; Overgaard-Hansen, O; Pedersen, EB; Robbins, TW; Sahakian, BJ; Savulich, G; Segerberg, T; Stenbæk, DS; Svart, N; Søndergaard, A | 1 |
| Itai, E; Jitsuiki, H; Kawato, M; Kurata, K; Mantani, A; Okada, G; Okamoto, Y; Sakai, Y; Shibakawa, M; Shinzato, H; Tamura, T; Yamamoto, O; Yamashita, H; Yokota, N; Yoshioka, T | 1 |
| Armand, S; Frokjaer, VG; Giraldi, A; Joergensen, MB; Knudsen, GM; Nielsen, JH; Stenbaek, DS; Weber, S | 1 |
| Chen, X; Cui, J; Feng, L; Feng, Y; Jin, Y; Liu, R; Wang, G; Wang, Y; Wu, H; Zhang, S; Zhang, Z; Zhou, J; Zhou, Y | 1 |
| Artursson, P; Blumenfeld, Z; Cohen, BN; Dougherty, DA; Grant, SN; Hammar, R; Kim, CH; Knox, HJ; Lester, HA; Looger, L; Luebbert, L; Marvin, JS; Muthusamy, AK; Nichols, AL; Walton, DP | 1 |
| Carhart-Harris, RL; Erritzoe, D; Giribaldi, B; Nutt, DJ; Weiss, B | 1 |
| Bhat, V; Dama, M; Demchenko, I; Frey, BN; Kennedy, SH; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Ravindran, AV; Rotzinger, S; Tassone, VK; Wu, M | 1 |
| Cao, Q; Rao, Y; Yang, R; Zhao, J | 1 |
| Cao, B; Frey, BN; Ho, K; Kennedy, SH; Lam, RW; Liu, YS; Milev, R; Müller, DJ; Nunez, JJ; Rotzinger, S; Soares, CN; Taylor, VH; Uher, R | 1 |
| Fang, J; Gao, S; Guo, C; He, J; Liu, Y; Lu, X; Luo, Y; Ma, Y; Rong, P; Sun, J; Zhang, Z | 1 |
| He, Y; Liu, M; Ren, S; Sun, Z; Wang, G; Wang, Y; Yang, J; Ye, J; Zhang, G; Zhao, Y; Zheng, P; Zhou, J | 1 |
| Fan, X; Ji, Z; Liu, X; Wang, X; Zhang, L | 1 |
| Lu, Z; Wang, Y; Xun, G | 1 |
| Lin, X; Miao, M; Song, X; Wang, C; Yin, J | 1 |
| Berlim, MT; Dos Santos, NR; Richard-Devantoy, S; Turecki, G | 1 |
| Grzenda, A; Laird, KT; Lavretsky, H; Siddarth, P; Yeargin, J | 1 |
| Dvojkovic, A; Jevtovic, S; Konjevod, M; Kusevic, Z; Mihaljevic Peles, A; Nedic Erjavec, G; Nikolac Perkovic, M; Pivac, N; Sagud, M; Svob Strac, D; Tudor, L; Vuksan Cusa, B; Zivkovic, M | 1 |
| Amaro, E; Benseñor, IM; Brunoni, AR; Bueno, PV; Bulubas, L; Busatto, G; Duran, F; Gattaz, W; Goerigk, S; Keeser, D; Lotufo, PA; Mezger, E; Padberg, F; Suen, P | 1 |
| Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, MS; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Lee, JS; Park, JH; Park, SW; Seo, WK; Sohn, SI | 1 |
| Kennedy, SH; Larsen, KG; Reines, EH; Thase, ME | 1 |
| Alciati, A; Caldirola, D; Cuniberti, F; Daccò, S; De Berardis, D; Perna, G | 1 |
| Brandt, IM; Fisher, PM; Frokjaer, VG; Ganz, M; Jorgensen, MB; Knudsen, GM; Köhler-Forsberg, K; Ozenne, B; Poulsen, A | 1 |
| Arns, M; Eebes, M; Rush, AJ; van der Vinne, N; van Putten, MJAM; Vollebregt, MA | 1 |
| Belluomo, I; Bersani, G; Bigio, B; Bowles, NP; Caroti, E; Cuoco, V; Di Lallo, VD; Fanelli, F; Iannitelli, A; Marconi, M; Nasca, C; Nicoletti, F; Pacitti, F; Quartini, A; Weisz, F; Xenos, D | 1 |
| Castellanos, FX; Li, JT; Li, K; Li, L; Si, TM; Su, YA; Wu, YK; Yan, CG | 1 |
| Chakrabarty, T; Frey, BN; Kennedy, SH; Lam, RW; McInerney, SJ; Milev, RV; Müller, DJ; Rotzinger, S; Torres, IJ | 1 |
| Fan, Y; Li, G; Li, H; Wang, X | 1 |
| Bhat, V; Chakrabarty, T; Frey, BN; Giacobbe, P; Kennedy, SH; Lam, RW; Lou, W; McInerney, S; Michalak, EE; Milev, RV; Morton, E; Müller, DJ; Parikh, SV; Rotzinger, S | 1 |
| Allen, TA; Frey, BN; Harkness, KL; Kennedy, SH; Lam, RW; Milev, R; Mueller, DJ; Quilty, LC; Uher, R | 1 |
| Bousman, CA; Li, JT; Lin, JY; Liu, Q; Lv, XZ; Si, TM; Su, YA; Tian, L; Yu, X | 1 |
4 review(s) available for escitalopram and Depression, Involutional
| Article | Year |
|---|---|
A Review of Clinical Studies Assessing the Therapeutic Efficacy of Escitalopram: A Step Towards Development.
Topics: Depressive Disorder, Major; Escitalopram; Humans; Quality of Life | 2023 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Fluoxetine; Humans; Imipramine; Network Meta-Analysis; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2022 |
Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors | 2023 |
Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review.
Topics: Adult; Antidepressive Agents; Aripiprazole; Child; Child Abuse; Clinical Decision-Making; Clinical Trials as Topic; Depressive Disorder, Major; Escitalopram; Humans; Observational Studies as Topic; Precision Medicine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2021 |
28 trial(s) available for escitalopram and Depression, Involutional
| Article | Year |
|---|---|
Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder.
Topics: Adult; Cilostazol; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Escitalopram; Female; Humans; Inflammation; Male; Middle Aged; Outcome Assessment, Health Care; Phosphodiesterase 3 Inhibitors; Pilot Projects; Selective Serotonin Reuptake Inhibitors | 2021 |
Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine.
Topics: Circadian Rhythm; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Mirtazapine; Treatment Outcome | 2022 |
Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder.
Topics: Algorithms; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Humans; Quality of Life; Treatment Outcome | 2022 |
Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Female; Humans; Male; Serum Amyloid P-Component; Treatment Outcome | 2022 |
Increased global integration in the brain after psilocybin therapy for depression.
Topics: Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Hallucinogens; Humans; Psilocybin | 2022 |
Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Escitalopram; Humans; Pain; Pain Measurement; Treatment Outcome | 2022 |
Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report.
Topics: Antidepressive Agents; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Female; Humans; Male; Treatment Outcome | 2022 |
What is the effectiveness and safety of mirtazapine versus escitalopram in alleviating cancer-associated poly-symptomatology (the MIR-P study)? A mixed-method randomized controlled trial protocol.
Topics: Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Humans; Mirtazapine; Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Comparison of Functional and Structural Neural Network Features in Older Adults With Depression With vs Without Apathy and Association With Response to Escitalopram: Secondary Analysis of a Nonrandomized Clinical Trial.
Topics: Aged; Antidepressive Agents; Apathy; Depression; Depressive Disorder, Major; Escitalopram; Female; Humans; Neural Networks, Computer | 2022 |
White matter predicts tDCS antidepressant effects in a sham-controlled clinical trial study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Diffusion Tensor Imaging; Double-Blind Method; Escitalopram; Female; Humans; Transcranial Direct Current Stimulation; Treatment Outcome; White Matter | 2023 |
Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.
Topics: Acupuncture Points; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2023 |
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major; Escitalopram; Gyrus Cinguli; Humans; Magnetic Resonance Imaging | 2023 |
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multicenter Studies as Topic; Nortriptyline; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy.
Topics: Adult; Antidepressive Agents; Brain; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Female; Humans; Magnetic Resonance Imaging; Psychotherapy | 2023 |
Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study.
Topics: Bayes Theorem; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Healthy Volunteers; Humans; Infant, Newborn; Selective Serotonin Reuptake Inhibitors | 2023 |
Examining the usefulness of the brain network marker program using fMRI for the diagnosis and stratification of major depressive disorder: a non-randomized study protocol.
Topics: Brain; Brain Mapping; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging; Prospective Studies | 2023 |
Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological | 2023 |
Effects of 12-week escitalopram treatment on resting-state functional connectivity of large-scale brain networks in major depressive disorder.
Topics: Antidepressive Agents; Brain; Brain Mapping; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging | 2023 |
Repetitive transcranial magnetic stimulation in the treatment of middle-aged and elderly major depressive disorder: A randomized controlled trial.
Topics: Administration, Oral; Aged; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Escitalopram; Humans; Middle Aged; Transcranial Magnetic Stimulation | 2023 |
Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Cognition; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2024 |
The network structure of core depressive symptom-domains in major depressive disorder following antidepressant treatment: a randomized clinical trial.
Topics: Adult; Affect; Antidepressive Agents; Cognitive Dysfunction; Cross-Sectional Studies; Depressive Disorder, Major; Desvenlafaxine Succinate; Escitalopram; Fatigue; Female; Humans; Longitudinal Studies; Male; Normal Distribution; Psychopathology; Suicide | 2021 |
Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Memantine; Transcriptome; Treatment Outcome | 2021 |
Prefrontal resting-state connectivity and antidepressant response: no associations in the ELECT-TDCS trial.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Female; Gray Matter; Humans; Male; Prefrontal Cortex; Rest; Transcranial Direct Current Stimulation; Treatment Outcome | 2021 |
Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2021 |
Patient Response Trajectories in Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2020 |
Eight-week antidepressant treatment reduces functional connectivity in first-episode drug-naïve patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Cerebral Cortex; Connectome; Default Mode Network; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Nerve Net; Treatment Outcome; Young Adult | 2021 |
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Biomarkers; Canada; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Drug Therapy, Combination; Escitalopram; Female; Humans; Male; Middle Aged; Young Adult | 2021 |
The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study.
Topics: China; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2021 |
34 other study(ies) available for escitalopram and Depression, Involutional
| Article | Year |
|---|---|
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Cell Line; Depressive Disorder, Major; Drug Partial Agonism; Drug Stability; Hippocampus; Humans; In Vitro Techniques; Microsomes, Liver; Oocytes; Piperazines; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Sulfides; Vortioxetine; Xenopus | 2011 |
Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder.
Topics: Biomarkers; Brain Mapping; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging | 2022 |
Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report.
Topics: Aged; Aging; Antidepressive Agents; Brain; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Escitalopram; Humans; Treatment Outcome | 2021 |
Dimensions of temperament and character as predictors of antidepressant discontinuation, response and adverse reactions during treatment with nortriptyline and escitalopram.
Topics: Antidepressive Agents; Character; Depressive Disorder, Major; Escitalopram; Humans; Nortriptyline; Personality Inventory; Temperament | 2023 |
Effects of escitalopram therapy on resting-state functional connectivity of subsystems of the default mode network in unmedicated patients with major depressive disorder.
Topics: Brain; Brain Mapping; Default Mode Network; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging; Neural Pathways | 2021 |
Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report.
Topics: Anxiety; Depression; Depressive Disorder, Major; Escitalopram; Humans; Treatment Outcome | 2022 |
Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study.
Topics: Biomarkers; Canada; Depression; Depressive Disorder, Major; Escitalopram; Humans | 2023 |
Successful treatment for major depressive disorder with psychotic features with addition of asenapine on escitalopram.
Topics: Antipsychotic Agents; Citalopram; Depressive Disorder, Major; Dibenzocycloheptenes; Double-Blind Method; Escitalopram; Humans; Treatment Outcome | 2022 |
Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Humans; ROC Curve; Treatment Outcome; Venlafaxine Hydrochloride | 2022 |
Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.
Topics: Aged; Citalopram; Depressive Disorder, Major; Escitalopram; Humans; Long QT Syndrome; Psychotropic Drugs; Quetiapine Fumarate | 2023 |
The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; C-Reactive Protein; Citalopram; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Follow-Up Studies; Humans; Prospective Studies; Treatment Outcome | 2022 |
Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.
Topics: Aripiprazole; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Escitalopram; Humans; Treatment Outcome | 2022 |
Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Humans; Italy; Paroxetine; Retrospective Studies; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Effects of escitalopram therapy on functional brain controllability in major depressive disorder.
Topics: Antidepressive Agents; Brain; Citalopram; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging | 2022 |
Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder.
Topics: Depressive Disorder, Major; Escitalopram; Humans; Kynurenine; Magnetic Resonance Imaging; Prefrontal Cortex; Transcranial Magnetic Stimulation | 2022 |
Binding potential changes of SERT in patients with depression are associated with remission: A prospective [¹²³I]β-CIT-SPECT study.
Topics: Brain; Depression; Depressive Disorder, Major; Escitalopram; Humans; Prospective Studies; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon | 2023 |
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study.
Topics: Aripiprazole; Biomarkers; Canada; Depressive Disorder, Major; Double-Blind Method; Endocannabinoids; Escitalopram; Genome-Wide Association Study; Humans; RNA, Messenger; Treatment Outcome | 2022 |
Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report.
Topics: Biomarkers; Brain; Canada; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging | 2022 |
Sex differences on the response to antidepressants and psychobiotics following early life stress in rats.
Topics: Animals; Antidepressive Agents; Antioxidants; Depressive Disorder, Major; Escitalopram; Female; Ketamine; Male; Rats; Rats, Wistar; Sex Characteristics; Stress, Psychological | 2022 |
Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder.
Topics: Benzodiazepines; Citalopram; Depressive Disorder, Major; Escitalopram; Ethanol; Humans; Retrospective Studies | 2023 |
Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Fluoxetine; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 2023 |
Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane.
Topics: Animals; Citalopram; Depressive Disorder, Major; Endoplasmic Reticulum; Escitalopram; Fluoxetine; Humans; Mammals; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2023 |
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.
Topics: Clinical Trials as Topic; Depression; Depressive Disorder, Major; Escitalopram; Humans; Psilocybin; Psychiatric Status Rating Scales; Reproducibility of Results | 2023 |
The course of insomnia symptoms during the acute treatment of major depressive disorder: A CAN-BIND-1 report.
Topics: Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Humans; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2023 |
Response trajectories during escitalopram treatment of patients with major depressive disorder.
Topics: Canada; Depressive Disorder, Major; Escitalopram; Humans; Treatment Outcome | 2023 |
Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for modulating the brain activity in mild to moderate major depressive disorder: An fMRI study.
Topics: Acupuncture Points; Brain; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging | 2023 |
Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder.
Topics: Amino Acids; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Humans; Multiomics; Treatment Outcome | 2023 |
Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients.
Topics: Adolescent; Adult; Aged; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Escitalopram; Female; Humans; Longitudinal Studies; Male; Middle Aged; Serotonin; Vortioxetine; Young Adult | 2021 |
Reward processing in major depressive disorder and prediction of treatment response - Neuropharm study.
Topics: Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Humans; Magnetic Resonance Imaging; Reward | 2021 |
EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial.
Topics: Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Electroencephalography; Escitalopram; Feasibility Studies; Humans; Prescriptions; Prospective Studies; Treatment Outcome | 2021 |
Inverse correlation between plasma 2-arachidonoylglycerol levels and subjective severity of depression.
Topics: Arachidonic Acids; Depression; Depressive Disorder, Major; Endocannabinoids; Escitalopram; Glycerides; Humans | 2021 |
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Aripiprazole; Canada; Depressive Disorder, Major; Drug Monitoring; Drug Therapy, Combination; Escitalopram; Female; Humans; Male; Physical Functional Performance; Psychiatric Status Rating Scales; Quality of Life; Social Interaction; Treatment Outcome | 2021 |
Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report.
Topics: Aripiprazole; Depression; Depressive Disorder, Major; Escitalopram; Humans; Neuroticism | 2021 |
Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram.
Topics: Anxiety; Citalopram; Depressive Disorder, Major; Escitalopram; Genetic Variation; Genome-Wide Association Study; Humans; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2021 |